Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Genetic Characterization of Resistance to Extended-Spectrum β-Lactams in Klebsiella oxytoca Isolates Recovered from Patients with Septicemia at Hospitals in the Stockholm Area

Shang Wei Wu, Kathrine Dornbusch, Göran Kronvall
Shang Wei Wu
The Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute and Karolinska Hospital, 171 76 Stockholm, Sweden,and
Laboratory of Microbiology, The Rockefeller University, New York, New York 10021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrine Dornbusch
The Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute and Karolinska Hospital, 171 76 Stockholm, Sweden,and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Göran Kronvall
The Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute and Karolinska Hospital, 171 76 Stockholm, Sweden,and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.5.1294
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Two β-lactamase gene regions were characterized by DNA sequencing in eight clinical isolates of Klebsiella oxytoca. TheblaOXY-2a region encoded a β-lactamase nearly identical to OXY-2 (one amino acid residue substituted) and conferred aztreonam and cefuroxime resistance on the K. oxytoca isolates. Overproduction of OXY-2a was caused by a G-to-A substitution of the fifth nucleotide in the −10 consensus sequence ofblaOXY-2a. TheblaOXY-1a was identified in a susceptible strain, and the OXY-1a enzyme differed from OXY-1 by two amino acid residues.

Since the early 1980s, isolates ofKlebsiella oxytoca have been recognized as clinically significant and an indication for therapy (17). Clinical isolates of Klebsiella spp. resistant to cefotaxime, ceftazidime, or aztreonam have been increasingly reported (6, 12, 14). These bacteria can develop resistance to the newer cephalosporins and aztreonam by acquisition of plasmid-located extended-spectrum β-lactamases (ESBLs) (7, 18, 25) or by mutations giving rise to the hyperproduction of chromosomal β-lactamases (15). In wild-typeK. oxytoca, chromosomal β-lactamases are constitutively produced at low levels which are sufficient to affect the organism’s susceptibility to ampicillin, amoxicillin, carbenicillin, and ticarcillin (17). Overproduction of these β-lactamases, however, confers resistance to penicillins, cephalosporins, and aztreonam (8); in most cases this overproduction results from a mutation in the promoter region of the β-lactamase gene (9, 11). Molecular cloning and DNA sequencing have shown that the chromosomal β-lactamase genes in K. oxytoca can be divided into two main groups: blaOXY-1 andblaOXY-2 (11). These two categories of β-lactamase genes show 89.7% homology in DNA sequences and belong to functional group 2be of the ESBLs (4) and Ambler class A (1).

In previous studies (27, 28), 11 clinical isolates ofK. oxytoca were found to be resistant to aztreonam and cefuroxime (MIC of >16 μg/ml) but susceptible to cefotaxime, ceftazidime, and imipenem (MICs of <4 μg/ml). The bacteria isolated in these previous studies belonged to three subgroups based on their plasmid profiles (27, 28). By isoelectric focusing, a single, common β-lactamase with a pI of 5.25, designated KH, was observed in the strains. The resistance could not be transferred to Escherichia coli XAC and C600 by transformation and conjugation, suggesting a chromosomal location for the β-lactamase gene. Furthermore, the substrate profile of the KH β-lactamase exhibited the hydrolysis of aztreonam characteristic of the enzymes of the K. oxytoca OXY family (10, 28). The aim of the present study was to characterize the genetic determinant for the ESBL produced by the K. oxytoca isolates recovered from hospitalized patients in the Stockholm area.

Seven of the previously reported cefuroxime- and aztreonam-resistantK. oxytoca isolates (27, 28) were further investigated in the present study. One susceptible strain ofK. oxytoca isolated during the same period from a patient in Karolinska Hospital was also included. E. coli DH5α was the host for the cloning experiment. Plasmid pACYC177 was used to construct cloning vector pLSK (low copy number, single cloning site, and kanamycin resistance) (Table1).

View this table:
  • View inline
  • View popup
Table 1.

Bacterial strains and plasmids used in this study

All standard nucleic acid techniques were carried out essentially as described by Ausubel et al. (2) and Sambrook et al. (20). Plasmid DNA was prepared by use of the Wizard Plus Minipreps or Midipreps DNA purification system (Promega, Madison, Wis.). Chromosomal DNA from the K. oxytocaisolates was prepared according to the procedure of Wilson (26). The quantity of recovered DNA was measured with a GeneQuant RNA-DNA calculator (Pharmacia Biotech, Ltd., Cambridge, England). Plasmid DNA was introduced intoE. coli by transformation with CaCl2-treated E. coli DH5α, as recommended by Ausubel et al. (2). The DNA sequence was determined by the dideoxy-chain termination method (21) with an automated DNA-sequencing system (model 377; PE/ABI, Foster City, Calif.). Nucleotide and deduced amino acid sequences were analyzed with the GCG program (Genetics Computer Group, Madison, Wis.) and Lasergene software (DNASTAR, Madison, Wis.).

Primer oligonucleotides are shown in Table2. To detect theblaOXY-1 gene, primers C and D were used to generate a 668-bp amplicon. Primers L and M were employed to detect blaOXY-2, producing a 723-bp PCR fragment. Primers KHUBI and KHDBI were designed based onblaOXY-2 (11) andblaRBI (13) sequences, and these primers were used to amplify the region covering the complete KH β-lactamase gene for cloning. Primers CYC7BI1 and CYC7BI2 were designed and employed to construct plasmid pLSK from plasmid pACYC177 (19). The 5′ nucleotides of the primers KHUBI, KHDBI, CYC7BI1, and CYC7BI2 were modified to create aBamHI restriction site (Table 2) in order to ligate the PCR products. The PCR was made with a PCR reagent kit according to the standard reaction recommended by the manufacturer (Perkin-Elmer Cetus, Branchburg, N.J.). Therefore, 100 ng of the chromosomal DNA from each of the K. oxytoca isolates and 40 pmol of each primer were included in a 100-μl reaction mixture. PCR amplification was performed in a DNA Thermal Cycler 480 (Perkin-Elmer Cetus) with the following temperature profiles: 94°C for 5 min; 30 cycles of 94°C for 1 min, 60 (for blaOXY-1) or 55°C (forblaOXY-2) for 1 min, 72°C for 1 min, and 72°C for 5 min; and holding at 4°C (16).

View this table:
  • View inline
  • View popup
Table 2.

Oligonucleotides for detection and amplification ofblaOXY regions

The bacterial strains were grown in Luria-Bertani medium (Difco Laboratories, Detroit, Mich.) with aeration at 37°C. Kanamycin (Sigma, St. Louis, Mo.) was added at 50 μg/ml for selection and maintenance of pLSK plasmids. MICs of cefuroxime, aztreonam, cefotaxime, ceftazidime, and imipenem for the K. oxytoca isolates and E. coli transformants were determined by a microdilution method (27).

To determine whether the gene for KH β-lactamase is located on a chromosome or a plasmid, one strain from each plasmid subgroup of the K. oxytoca isolates was studied. Chromosomal and plasmid DNA preparations from strains KH78 (group 1), KH11 (group 2), and NBL63 (group 3) were used as templates for PCR amplification. Under the recommended conditions, PCR products of 0.68 kb for blaOXY-1(primer pair C-D) and 0.72 kb for blaOXY-2(primer pair L-M) were obtained from the chromosomal DNA templates of strains KH11, KH78, and NBL63. However, no PCR product was obtained for blaOXY-1 (primer pair C-D) or forblaOXY-2 (primer pair L-M) when the plasmid DNA preparations of these strains were used as templates.

The region including the entire KH β-lactamase gene was amplified from the chromosomal DNA of the K. oxytocaisolates by using primers KHUBI and KHDBI. All PCR products from strains KH11, KH66, KH78, and NBL63 were sequenced. The 1,062-bp nucleotide sequence containing the β-lactamase gene from strain KH11 and the deduced amino acid sequence are shown in Fig.1. The 867-bp nucleotide sequence (positions 147 to 1016) encoded a β-lactamase of 289 amino acid residues. The nucleotide sequence of this β-lactamase was nearly identical (99.8%) to that of the wild-type OXY-2 β-lactamase from K. oxytoca SL911 (11). The amino acid sequence of the β-lactamase was different from that of OXY-2 by only one residue; Ala-13 (ABL Ala-10) (1) was absent in the enzyme from strain KH11. On the basis of this high degree of similarity, KH β-lactamase was redesignated OXY-2a, and the KH determinant was redesignated blaOXY-2a. TheblaOXY-2a gene was preceded by a promoter, in which TTGTCA and GATAAT were the −35 and −10 consensus sequences, respectively, and by a putative Shine-Dalgarno sequence (AAGGAA). The nucleotide and amino acid sequences of the β-lactamase genes and proteins of strains KH78 and NBL63 were identical to those of strain KH11. The β-lactamase from the susceptible K. oxytoca strain KH66 was highly similar to wild-type OXY-1 in amino acid sequence (99.3% identity), and the DNA equences encoding the two proteins were also very similar (98.9% identity) (9). The major difference between the proteins was that Leu-262 (ABL Leu-261) and Glu-278 (ABL Glu-277) (1) in OXY-1 were respectively substituted with Pro-262 (ABL 261) and Lys-278 (ABL 277) in KH66. Accordingly, the KH66 protein was designated OXY-1a.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Nucleotide sequence of theblaOXY-2a region of K. oxytocaKH11. Numbering starts at the 5′ end of primer KHUBI and ends at the complementary nucleotide of the 5′ end of primer KHDBI. The start codon and consensus sequences are underlined. The stop codon is designated with an asterisk. The deduced polypeptide sequence is indicated. S.D., Shine-Dalgarno site.

The promoter regions from each of the eight K. oxytocaisolates were sequenced. The promoters for the β-lactamase genes in all the isolates but KH66 had the same consensus sequence as that forblaOXY-2a in the strain KH11. Contrasting with the promoter sequences of wild-type blaOXY-2(TTGTCA for −35 and GATAGT for −10), theblaOXY-2a promoters had a substitution (G→A) of the fifth base in the −10 consensus sequence. The promoter ofblaOXY-1a in KH66 was identical to that of wild-type blaOXY-1 (9).

The DNA fragment containing the replication origin and kanamycin resistance gene in plasmid pACYC177 was PCR amplified by using the primers CYC7BI1 and CYC7BI2. After digestion with BamHI, the fragment was ligated with BamHI digests of PCR-generated blaOXY-2a andblaOXY-1a regions from Klebsiellastrains KH11 and KH66 to form recombined plasmids pLSKSW-7 and pLSKSW-8, respectively. The two plasmids were then transformed into E. coli DH5α for the expression of resistance to β-lactam antibiotics. The E. coli(pLSKSW-7) transformant and K. oxytoca KH11 showed similar antibiograms which indicated resistances to aztreonam and cefuroxime and intermediate susceptibilities or susceptibilities to cefotaxime, ceftazidime, and imipenem (Table3). The E. coli(pLSKSW-8) transformant and K. oxytoca KH66 similarly displayed no significant resistances to the β-lactam antibiotics tested (Table 3).

View this table:
  • View inline
  • View popup
Table 3.

Antibiotic susceptibility of K. oxytocastrains and E. coli transformants

In the present study, by PCR-based cloning and sequencing techniques, the chromosomally encoded OXY-2a was confirmed to be responsible for β-lactam resistance in the K. oxytoca isolates recovered from patients in the Stockholm area during 1987 (27, 28). The high identities of the OXY-2a coding regions and promoter sequences in the K. oxytoca strains suggest a common origin for the β-lactam-resistantK. oxytoca isolates. The mutation observed in theblaOXY-2a promoters may have resulted in the overexpression of this β-lactamase, thereby conferring resistance to β-lactam antibiotics on K. oxytoca. Similar findings have been reported by others (3, 8, 9, 17, 22-24).

Of the two substitutions observed in OXY-1a, one of them (Pro-261) is located in a hydrophobic pocket and the other (Lys-277) is quite close to the homologous active site (Asp-276) of TEM β-lactamases (5).

In this study, the primers specific to OXY-1 and OXY-2 cross-amplified. This may have been caused by our use of a large amount of template DNA and the high homology of the two genes. This cross-amplification suggests that PCR conditions should be carefully established. The parallel PCRs for blaOXY-1 andblaOXY-2 should be set with the intention of differentiating the two genes. On the other hand, PCR might be performed with one of the primer pairs, and the PCR product might be directly sequenced to identify the genes.

The effort to construct a recombinant plasmid by ligating two PCR-generated DNA fragments was successful and demonstrated a simple, fast, and straightforward approach for cloning.

Nucleotide sequence accession numbers.The nucleotide sequences described in this paper have been submitted to EMBL-GenBank under accession no. Y17714 for blaOXY-2aand no. Y17715 for blaOXY-1a.

ACKNOWLEDGMENTS

We thank Robyn T. Bilinski for the valuable effort she made in the preparation of the manuscript.

FOOTNOTES

    • Received 13 August 1998.
    • Returned for modification 29 January 1999.
    • Accepted 10 February 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Ambler R. P.,
    2. Coulson A. F.,
    3. Frere J. M.,
    4. Ghuysen J. M.,
    5. Joris B.,
    6. Forsman M.,
    7. Levesque R. C.,
    8. Tiraby G.,
    9. Waley S. G.
    A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276 1991 269 270
    OpenUrlFREE Full Text
  2. 2.↵
    1. Ausubel F. M.,
    2. Brent R.,
    3. Kingston R. E.,
    4. Moore D. D.,
    5. Seidman J. G.,
    6. Smith J. A.,
    7. Struhl K.
    Short protocols in molecular biology. 1992 John Wiley New York, N.Y
  3. 3.↵
    1. Buirma R. J.,
    2. Horrevorts A. M.,
    3. Wagenvoort J. H.
    Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. The 1990 Dutch surveillance study. Scand. J. Infect. Dis. Suppl. 78 1991 35 44
    OpenUrlPubMed
  4. 4.↵
    1. Bush K.,
    2. Jacoby G. A.,
    3. Medeiros A. A.
    A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39 1995 1211 1233
    OpenUrlFREE Full Text
  5. 5.↵
    1. Caniça M. M.,
    2. Caroff N.,
    3. Barthélémy M.,
    4. Labia R.,
    5. Krishnamoorthy R.,
    6. Paul G.,
    7. Dupret J.-M.
    Phenotypic study of resistance of β-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276. Antimicrob. Agents Chemother. 42 1998 1323 1328
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Chanal C. M.,
    2. Sirot D. L.,
    3. Petit A.,
    4. Labia R.,
    5. Morand A.,
    6. Sirot J. L.,
    7. Cluzel R. A.
    Multiplicity of TEM-derived β-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids. Antimicrob. Agents Chemother. 33 1989 1915 1920
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Chardon H.,
    2. Fosse T.,
    3. Labia R.,
    4. Nicolas M. H.,
    5. Poyart-Salmeron C.,
    6. Sirot J.,
    7. Sirot D.,
    8. Vernon M.
    Multifactorial analysis of the phenotypes for β-lactams of 1044 Escherichia coli strains. Pathol. Biol. (Paris) 41 1993 337 342
    OpenUrlPubMed
  8. 8.↵
    1. Fournier B.,
    2. Arlet G.,
    3. Lagrange P. H.,
    4. Philippon A.
    Klebsiella oxytoca: resistance to aztreonam by overproduction of the chromosomally encoded β-lactamase. FEMS Microbiol. Lett. 116 1994 31 36
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Fournier B.,
    2. Lu C. Y.,
    3. Lagrange P. H.,
    4. Krishnamoorthy R.,
    5. Philippon A.
    Point mutation in the Pribnow box, the molecular basis of β-lactamase overproduction in Klebsiella oxytoca. Antimicrob. Agents Chemother. 39 1995 1365 1368
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Fournier B.,
    2. Roy P. H.
    Variability of chromosomally encoded β-lactamases from Klebsiella oxytoca. Antimicrob. Agents Chemother. 41 1997 1641 1648
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Fournier B.,
    2. Roy P. H.,
    3. Lagrange P. H.,
    4. Philippon A.
    Chromosomal β-lactamase genes of Klebsiella oxytoca are divided into two main groups, blaOXY-1 and blaOXY-2. Antimicrob. Agents Chemother. 40 1996 454 459
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Gutmann L.,
    2. Kitzis M. D.,
    3. Billot-Klein D.,
    4. Goldstein F.,
    5. Tran Van Nhieu G.,
    6. Lu T.,
    7. Carlet J.,
    8. Collatz E.,
    9. Williamson R.
    Plasmid-mediated β-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Rev. Infect. Dis. 10 1988 860 866
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Kimura K.,
    2. Arakawa Y.,
    3. Ohsuka S.,
    4. Ito H.,
    5. Suzuki K.,
    6. Kurokawa H.,
    7. Kato N.,
    8. Ohta M.
    Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob. Agents Chemother. 40 1996 1988 1994
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Knothe H.,
    2. Shah P.,
    3. Krcmery V.,
    4. Antal M.,
    5. Mitsuhashi S.
    Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11 1983 315 317
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Labia R.,
    2. Morand A.,
    3. Guionie M.,
    4. Heintz M.,
    5. Pitton J. S.
    Klebsiella oxytoca β-lactamases: study of their action on 3d-generation cephalosporins. Pathol. Biol. (Paris) 34 1986 611 615
    OpenUrlPubMed
  16. 16.↵
    1. Liu Y.,
    2. Mee B. J.,
    3. Mulgrave L.
    Identification of clinical isolates of indole-positive Klebsiella spp., including Klebsiella planticola, and a genetic and molecular analysis of their β-lactamases. J. Clin. Microbiol. 35 1997 2365 2369
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Livermore D. M.
    β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8 1995 557 584
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Reig R.,
    2. Roy C.,
    3. Hermida M.,
    4. Teruel D.,
    5. Coira A.
    A survey of beta-lactamases from 618 isolates of Klebsiella spp. J. Antimicrob. Chemother. 31 1993 29 35
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Rose R. E.
    The nucleotide sequence of pACYC177. Nucleic Acids Res. 16 1988 356
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Sambrook J.,
    2. Fritsch E. F.,
    3. Maniatis T.
    Molecular cloning: a laboratory manual 2nd ed. 1989 Cold Spring Harbor Laboratory Press Cold Spring Harbor, N.Y
  21. 21.↵
    1. Sanger F.,
    2. Nicklen S.,
    3. Coulson A. R.
    DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74 1977 5463 5467
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Shah P. M.,
    2. Asanger R.,
    3. Kahan M.
    Incidence of multi-resistance in gram negative aerobes from intensive care units of 10 German hospitals. Scand. J. Infect. Dis. 78 (Suppl.) 1991 22 34
    OpenUrl
  23. 23.↵
    1. Sirot D. L.,
    2. Goldstein F. W.,
    3. Soussy C. J.,
    4. Courtieu A. L.,
    5. Husson M. O.,
    6. Lemozy J.,
    7. Meyran M.,
    8. Morel C.,
    9. Perez R.,
    10. Quentin-Noury C.,
    11. Reverdy M. E.,
    12. Scheftel J. M.,
    13. Rosenbaum M.,
    14. Rezvani Y.
    Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob. Agents Chemother. 36 1992 1677 1681
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Snydman D. R.
    Clinical implications of multi-drug resistance in the intensive care unit. Scand. J. Infect. Dis. 78 (Suppl.) 1991 54 63
    OpenUrl
  25. 25.↵
    1. Venezia R. A.,
    2. Scarano F. J.,
    3. Preston K. E.,
    4. Steele L. M.,
    5. Root T. P.,
    6. Limberger R.,
    7. Archinal W.,
    8. Kacica M. A.
    Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin. Infect. Dis. 21 1995 915 923
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Wilson K.
    Preparation of genomic DNA from bacteria Current protocols in molecular biology Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A., Struhl K. 1 1987 2.4.1 2.4.5 Wiley Interscience Brooklyn, N.Y
    OpenUrl
  27. 27.↵
    1. Wu S. W.,
    2. Dornbusch K.,
    3. Goransson E.,
    4. Ransjo U.,
    5. Kronvall G.
    Characterization of Klebsiella oxytoca septicaemia isolates resistant to aztreonam and cefuroxime. J. Antimicrob. Chemother. 28 1991 389 397
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Wu S. W.,
    2. Dornbusch K.,
    3. Norgren M.,
    4. Kornvall G.
    Extended spectrum beta-lactamase from Klebsiella oxytoca, not belonging to the TEM or SHV family. J. Antimicrob. Chemother. 30 1992 3 16
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Genetic Characterization of Resistance to Extended-Spectrum β-Lactams in Klebsiella oxytoca Isolates Recovered from Patients with Septicemia at Hospitals in the Stockholm Area
Shang Wei Wu, Kathrine Dornbusch, Göran Kronvall
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1294-1297; DOI: 10.1128/AAC.43.5.1294

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Genetic Characterization of Resistance to Extended-Spectrum β-Lactams in Klebsiella oxytoca Isolates Recovered from Patients with Septicemia at Hospitals in the Stockholm Area
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genetic Characterization of Resistance to Extended-Spectrum β-Lactams in Klebsiella oxytoca Isolates Recovered from Patients with Septicemia at Hospitals in the Stockholm Area
Shang Wei Wu, Kathrine Dornbusch, Göran Kronvall
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1294-1297; DOI: 10.1128/AAC.43.5.1294
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

bacteremia
Klebsiella
Klebsiella Infections
beta-lactam resistance
beta-lactamases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596